A
AURA
PEPTIDE RESEARCH
Growth hormone

Tesamorelin

Half-life: ~30 minutes

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of native GHRH with a trans-3-hexenoic acid modification. Marketed under the brand name Egrifta®, tesamorelin is the only GHRH analog currently FDA-approved for therapeutic use—specifically for reducing…

Category
Growth hormone
Half-life
~30 minutes
Typical route
Subcutaneous

Research benefits

FDA-approved for reducing visceral adipose tissue

Stimulates natural pulsatile growth hormone release

Preserves hypothalamic-pituitary feedback regulation

Improves trunk fat and waist circumference

May reduce liver fat in NAFLD

Potential cognitive benefits in aging populations

Favorable lipid profile effects

Does not significantly impair glucose metabolism

Research applications

HIV-associated lipodystrophy (FDA-approved)

Active research area with published studies

Non-alcoholic fatty liver disease (NAFLD)

Active research area with published studies

Cognitive function in aging and HIV

Active research area with published studies

Visceral obesity and metabolic syndrome

Active research area with published studies

Body composition optimization

Active research area with published studies

Cardiovascular risk markers

Active research area with published studies

Age-related GH decline

Active research area with published studies

Liver enzyme improvement

Active research area with published studies

Calculate your Tesamorelin dose

Use our free reconstitution calculator for exact draw units, half-life curves, and cycle schedules.

Open calculator →
Important. This information is educational only. Tesamorelin is sold as a research peptide and is not FDA-approved for human therapeutic use. Do not use during pregnancy, breastfeeding, or active malignancy. Consult a qualified healthcare provider before beginning any peptide protocol. Peptide Aura accepts no responsibility for how this information is used.